SBRT plus immunotherapy and chemotherapy for advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a combination of radiation therapy (SBRT), two immunotherapy drugs (Ipilimumab and Sintilimab), and two chemotherapy drugs (Nab-Paclitaxel and Gemcitabine) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this treatment can control the cancer better than standard options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with pancreatic ductal adenocarcinoma (a common type of pancreatic cancer).
- Your cancer is locally advanced and has not spread to other organs (like the liver or brain).
- You are between 18 and 75 years old.
- You feel fairly well, able to handle daily activities (ECOG score 0-1).
- You have not had any chemotherapy or immunotherapy for advanced pancreatic cancer before.
- You have at least one tumor that can be measured on scans.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new combination of super-precise radiation (guided SBRT), standard chemotherapy, and a newer immune medicine called Ivonescimab can slow or shrink pancreatic tumors that cannot be removed by surgery. The goal is to find a more effective treatment option.
This trial tests a new immunotherapy drug (ivonescimab) combined with targeted radiation and chemotherapy for people with pancreatic cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a new immunotherapy drug called ivonescimab combined with chemotherapy, with or without another experimental drug (AK117), for people with pancreatic cancer that has spread. The goal is to see if adding these therapies can help shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs (NC410 plus chemotherapy and nivolumab, with or without ipilimumab) for people with metastatic pancreatic cancer who haven't had treatment yet. The goal is to see if adding these immunotherapy agents can help shrink or control the tumor.
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
This trial tests a new immunotherapy drug (adebrelimab) combined with a standard chemotherapy cocktail (NALIRIFOX) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination shrinks or controls the cancer better than chemo alone.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.